Vitamin D supplementation for prevention of mortality in adults
Cochrane Reviews, 07/11/2011Bjelakovic G et al.
Vitamin D in the form of vitamin D3 seems to decrease mortality in predominantly elderly women who are mainly in institutions and dependent care. Vitamin D2, alfacalcidol, and calcitriol had no statistically significant effect on mortality. Vitamin D3 combined with calcium significantly increased nephrolithiasis. Both alfacalcidol and calcitriol significantly increased hypercalcaemia.
The authors searched The Cochrane Library, MEDLINE, EMBASE, LILACS, the Science Citation Index Expanded, and Conference Proceedings Citation Index–Science (to January 2011).
They scanned bibliographies of relevant publications and asked experts and pharmaceutical companies for additional trials.
They included randomised trials that compared vitamin D at any dose, duration, and route of administration versus placebo or no intervention.
Vitamin D could have been administered as supplemental vitamin D (vitamin D3 (cholecalciferol) or vitamin D2 (ergocalciferol)) or an active form of vitamin D (1α–hydroxyvitamin D (alfacalcidol) or 1,25–dihydroxyvitamin D (calcitriol)).
Six authors extracted data independently.
Random–effects and fixed–effect model meta–analyses were conducted.
For dichotomous outcomes, they calculated the risk ratios (RR).
To account for trials with zero events, meta–analyses of dichotomous data were repeated using risk differences (RD) and empirical continuity corrections.
Risk of bias was considered in order to minimise risk of systematic errors.
Trial sequential analyses were conducted to minimise the risk of random errors.
Fifty randomised trials with 94,148 participants provided data for the mortality analyses.
Most trials included elderly women (older than 70 years).
Vitamin D was administered for a median of two years.
More than one half of the trials had a low risk of bias.
vitamin D decreased mortality (RR 0.97, 95% confidence interval (CI) 0.94 to 1.00, I2 = 0%).
When the different forms of vitamin D were assessed separately, only vitamin D3 decreased mortality significantly (RR 0.94, 95% CI 0.91 to 0.98, I2 = 0%; 74,789 participants, 32 trials) whereas vitamin D2, alfacalcidol, or calcitriol did not. Trial sequential analysis supported the finding regarding vitamin D3, corresponding to 161 individuals treated to prevent one additional death.
Vitamin D3 combined with calcium increased the risk of nephrolithiasis (RR 1.17, 95% CI 1.02 to 1.34, I2 = 0%). Alfacalcidol and calcitriol increased the risk of hypercalcaemia (RR 3.18, 95% CI 1.17 to 8.68, I2 = 17%).
Data on health–related quality of life and health economics were inconclusive.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.